Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional...

Keywords

MedicineCardiotoxicityMucositisDoxorubicinMetastatic breast cancerInternal medicineAnthracyclineVomitingNeutropeniaNauseaGastroenterologyBreast cancerCancerChemotherapy

Affiliated Institutions

Related Publications

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

Anne Hamilton , Laura Biganzoli , Robert E. Coleman +9 more

2002 Annals of Oncology 104 citations

Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

Tamar Safra , Franco M. Muggia , Susan Jeffers +6 more

2000 Annals of Oncology 605 citations

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Anthony W. Tolcher , Steven Sugarman , Karen A. Gelmon +7 more

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is direc...

1999 Journal of Clinical Oncology 266 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon , Brian Leyland‐Jones , Steven Shak +9 more

Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.

2001 New England Journal of Medicine 11312 citations

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Publication Info

Year: 2004
Type: article
Volume: 15
Issue: 3
Pages: 440-449
Citations: 1672
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1672

OpenAlex

Cite This

APA Style

                            
                                
                                    E O’Brien, 
                                
                                    Nely Wigler, 
                                
                                    Moshe Inbar
                                
                                et al.
                            
                            (2004). 
                            Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. 
                            Annals of Oncology
                            , 15
                            (3)
                            , 440-449.
                            https://doi.org/10.1093/annonc/mdh097
                        

Identifiers

DOI: 10.1093/annonc/mdh097